aestheticmedguideAestheticMedGuide
Injectables

How Long Does Radiesse Last? Area-by-Area PMA Duration, Not One 12-to-18-Month Number

Radiesse duration is PMA- and area-specific. Manufacturer up-to-2-years is not the SSED table. Décolleté 1:2 is labeled; hyperdilute body is not.

Ran Chen
Ran Chen
27 min read · Published · Evidence-based

When patients and clinicians research calcium hydroxylapatite (CaHA) injectable implants, they frequently encounter an oversimplified claim: "Radiesse lasts 12 to 18 months," or the headline marketing assertion that "results have been shown to last up to 2 years."

Consumer med spa websites routinely treat Radiesse as a single uniform product with a fixed biological lifespan, conflating facial folds with dorsal hand rejuvenation, structural jawline sculpting, and off-label body tightening.

The clinical and regulatory reality established in FDA Premarket Approval (PMA) data is that there is no single "Radiesse duration." In the United States, calcium hydroxylapatite sits on two distinct PMA numbers held by applicant Merz North America, Inc.:

  1. P050037: Approved on December 22, 2006, for the restoration and correction of the signs of facial lipoatrophy in people with human immunodeficiency virus (HIV; 148 FDA PMA listing rows under Product Code LMH).
  2. P050052: Approved on December 22, 2006, for aesthetic subdermal implantation for the correction of moderate to severe facial wrinkles and folds (170 FDA PMA listing rows across Product Codes LMH and PKY).

Under PMA P050052, each anatomical indication has its own clinical trial cohort, validated grading scale, investigator-versus-subject endpoint, and last-visit responder denominator:

  • Nasolabial Folds (ORIG, 2006): Split-face randomized comparison against human collagen (N=117). The 3-month primary endpoint was non-inferiority on the Lemperle Rating Scale: 84.6% of Radiesse-treated folds scored at least 1 LRS point higher than control. The 6-month secondary superiority analysis was 78.6%. That is not an 18-month or 2-year primary table. Manufacturer "up to 2 years" tracks the Bass 2010 extension, in which 40% of folds remained improved at ≥30 months after the last treatment.
  • Dorsal Hands (Supplement S049, June 4, 2015; Product Code PKY): Blinded-evaluator MHGS responders were 64/85 (75.3%) at 3 months versus 1/29 (3.4%) delayed controls. Table 20 among remaining unretreated subjects was 15/22 (68.2%) at 12 months. The IFU states safety and effectiveness are unknown beyond 1 year in the hand.
  • Jawline (Supplement S129, September 1, 2021): Indicated strictly for RADIESSE (+) with factory-integrated 0.3% lidocaine in adults over 21. Blinded-evaluator MJAS responders at Week 12 were 93/123 (75.6%) versus 5/57 (8.8%) delayed control. The SSED's Week-48 retained-response figure is 76/113 (67.3%) among patients who had responded 12 weeks after their own initial treatment and who had Week-48 MJAS data—not 76 of the original 93, because 113 is larger than 93 and includes delayed-treatment patients after crossover.
  • Décolleté Wrinkles (Supplement S162, March 31, 2026): Panel-track approval for RADIESSE diluted 1:2 with 0.9% sterile saline (1.5 mL product : 3.0 mL saline in the trial), delivered via 22-gauge flexible cannula across three sessions (Day 1, Week 6, Week 12). Multiple-imputation MAS At Rest responders at Week 24 were 71.2% versus 6.3% control. Observed-case response was 54/89 (60.7%) at Week 60. The SSED prints no Week-84 MAS n/N.
  • Hyperdilute Body Tightening (Neck, Arms, Abdomen, Buttocks): Still entirely off-label in the United States. Zero FDA PMA listing rows exist for hyperdilute trade names. Labeled 1:2 saline dilution for décolleté is not a general body-tightening license.

Furthermore, unlike hyaluronic acid (HA) gels, calcium hydroxylapatite is not dissolvable with hyaluronidase. Complications cannot be enzymatically reversed.

For cross-material comparisons against poly-L-lactic acid, read our Sculptra vs. Radiesse guide and our analysis of how long Sculptra takes to work. For comparisons against hyaluronic acid duration, consult the Restylane PMA duration atlas and the Juvéderm PMA duration guide. Hand-specific tradeoffs are detailed in Radiesse vs. Restylane Lyft for hands. The operator PMA census, including the décolleté announcement, lives on the Merz Aesthetics portfolio page. For broad class differences, see biostimulators vs. HA fillers.

                  [Radiesse Portfolio Regulatory & Duration Architecture]

  Indication / SKU            PMA & Approval Date     Pivotal SSED Endpoints & Responders           Labeled / IFU Limits
  ─────────────────────────   ───────────────────     ──────────────────────────────────────────    ────────────────────
  Nasolabial Folds (Aesthetic) P050052 ORIG (2006)    M3 primary: 84.6% folds ≥1 LRS vs collagen    Unknown >3 yr face;
                              Product Code: LMH       M6 secondary: 78.6% (N=117)                   "Up to 2 years" (FAQ)
                                                      Bass 2010: 40% of folds improved at ≥30 mo
  ─────────────────────────   ───────────────────     ──────────────────────────────────────────    ────────────────────
  HIV Facial Lipoatrophy      P050037 ORIG (2006)    M3: 100% GAIS (N=100) | M6: 100% (N=98)       Medical reconstructive;
                              Product Code: LMH       Left cheek 4.7 mm → 7.1 mm at 6 months        Separate from NLF
  ─────────────────────────   ───────────────────     ──────────────────────────────────────────    ────────────────────
  Dorsal Hand Augmentation    P050052/S049 (2015)     M3: 75.3% (64/85) vs 3.4% control             Unknown >1 year;
                              Product Code: PKY       M12 Table 20 (unretreated): 68.2% (15/22)     Nodules persist to 1 yr
  ─────────────────────────   ───────────────────     ──────────────────────────────────────────    ────────────────────
  Jawline Contour             P050052/S129 (2021)     W12: 75.6% (93/123) vs 8.8% delayed control   RADIESSE (+) only;
                              Product Code: LMH       W48 retained: 67.3% (76/113) observed cases   Adults >21; deep plane
                                                      (not 76 of the original 93)
  ─────────────────────────   ───────────────────     ──────────────────────────────────────────    ────────────────────
  Décolleté Wrinkles          P050052/S162 (2026)     W24: 71.2% (MI, N=116) vs 6.3% control        Diluted 1:2 with saline;
                              Product Code: LMH       W60 (observed): 60.7% (54/89) responders      3 sessions (D1, W6, W12);
                                                      No Week-84 MAS table; 81/116 available        Unknown >84 weeks
  ─────────────────────────   ───────────────────     ──────────────────────────────────────────    ────────────────────
  Hyperdilute Body            Off-label               No US PMA duration table; 1:2 décolleté      Off-label; not licensed
  (Neck, Arms, Buttocks)      No US PMA approval      does not license 1:3+ body protocols        by S162 décolleté

Direct Answer: Does Radiesse Really Last 12 to 18 Months? Or 2 Years?

When evaluating clinical duration, patients must separate investigator-measured primary trial endpoints, observational extension studies, and manufacturer promotional copy:

  • What "Up to 2 Years" Actually Represents: The phrase "results have been shown to last up to 2 years" (prominently featured on consumer FAQ pages, citing Bass et al., Aesthetic Surgery Journal, 2010) does not mean the median patient maintains peak aesthetic correction for 24 months. Van Loghem et al. describe that extension as following 102 of the original 117 nasolabial-fold subjects, with retreatment offered between 6 and 12 months to balance asymmetry, then follow-up to 39 months. At least 30 months after the last Radiesse treatment, 40% of folds remained clinically improved. A 40% responder rate at 30 months is an upper-tail persistence signal after the last injection—not a median, and not the 6-month pivotal table. Sixty percent of evaluated folds were no longer scored improved.
  • The "Unknown Beyond" Ceilings in the Official Labeling: In the official FDA-approved Instructions for Use (IFU), Merz specifies explicit temporal boundaries where safety and effectiveness have not been established:
    • Facial indications (nasolabial folds): Safety and effectiveness beyond 3 years have not been investigated.
    • Dorsal hands: Safety and effectiveness beyond 1 year have not been investigated.
    • Décolleté: Safety and effectiveness beyond 84 weeks (approximately 19.5 months) have not been investigated.
  • Area-by-Area Duration Realities:
    • Nasolabial Folds: Rapid initial correction from the gel carrier. The pivotal SSED's primary endpoint is a 3-month LRS comparison versus collagen (84.6% of Radiesse folds scored ≥1 point higher). The 6-month secondary superiority analysis is 78.6%. There is no SSED median of 12 to 18 months. Literature reviews often quote a 12-to-18-month clinical envelope; that is not a last-visit table.
    • Dorsal Hands: Blinded-evaluator responder rate is 75.3% (64/85) at 3 months. Table 20's 68.2% (15/22) at 12 months is the shrinking unretreated remainder of 113 treated subjects (immediate plus delayed-treatment crossover), not an intent-to-treat rate for the original 85. The IFU unknown-beyond ceiling for the hand is 1 year.
    • Jawline Contour: Indicated exclusively for RADIESSE (+) with lidocaine. Primary response at Week 12 was 75.6% (93/123). The SSED then reports 76/113 (67.3%) still meeting responder criteria at Week 48 among patients who had responded 12 weeks after their own initial treatment and who had Week-48 data—before optional retreatment. Because 113 exceeds 93, that Week-48 fraction is not nested inside Table 12's immediate-treatment responders.
    • Décolleté (Chest Wrinkles): Requires an intensive multi-session protocol: three treatments spaced 6 weeks apart (Day 1, Week 6, Week 12) using a 1:2 saline dilution. Multiple imputation showed 71.2% responders at Week 24; observed response was 60.7% (54/89) at Week 60. Expecting a single undiluted syringe to fix chest wrinkles for 18 months ignores the clinical trial design.
  • Skip any quote that will not name the product, dilution, and area. An undifferentiated "Radiesse lasts 12 to 18 months" quote tells you nothing about whether the injector is placing undiluted product on the mandibular bone, injecting 1:2 saline dilution in the chest, or using an unstandardized 1:4 dilution on the neck. Furthermore, anyone promising 2 to 4 years of body tightening or suggesting that Radiesse can be dissolved if overfilled is providing inaccurate medical advice.

Mechanism of Action: The Two-Phase Biological Curve

To understand why Radiesse behaves differently from both hyaluronic acid fillers and pure biostimulators like Sculptra (poly-L-lactic acid), one must examine its composition and biphasic degradation:

                  [The Two-Phase Mechanism of Calcium Hydroxylapatite]

    Phase 1: Immediate Volume (Months 0–3)      Phase 2: Neocollagenesis & Remodeling (Months 3–18+)
  ┌────────────────────────────────────────┐  ┌─────────────────────────────────────────────────┐
  │ • 70% Aqueous Gel Carrier (Sodium CMC) │  │ • 30% Calcium Hydroxylapatite Microspheres      │
  │ • High Viscosity & Elastic Modulus     │  │ • 25–45 µm Smooth Spheres (No Phagocytosis)     │
  │ • Immediate Mechanical Projection      │  │ • Fibroblast Activation ──► Type I & III Collagen│
  │ • Gel Absorbed by Macrophages in 8–12 W│  │ • Elastin, Proteoglycans, Angiogenesis          │
  └────────────────────────────────────────┘  └─────────────────────────────────────────────────┘
                      │                                                │
                      ▼                                                ▼
              [Initial Placement] ──────────────────────────► [Durable Collagen Matrix]
              Immediate correction                            Microspheres degrade via normal
              driven by CMC carrier                           metabolism into calcium & phosphate

1. Composition: 30% CaHA Microspheres + 70% CMC Gel Carrier

Radiesse is formulated as a sterile, non-pyrogenic, semi-solid cohesive subdermal implant:

  • 30% Synthetic Calcium Hydroxylapatite (CaHA) Microspheres: Uniform, smooth spherical particles ranging from 25 to 45 microns (µm) in diameter. This precise calibration prevents microparticle phagocytosis by macrophages (which engulf particles smaller than 15 µm) while avoiding foreign-body giant cell reactions typical of irregular or sharp particles. CaHA is chemically and structurally identical to the mineral component of human bone and teeth.
  • 70% Aqueous Carboxymethylcellulose (CMC) Gel Carrier: Composed of USP sodium carboxymethylcellulose, glycerin, and high-purity water. The CMC carrier provides immediate mechanical lift, high elasticity (G-prime), and precise particle suspension.

2. The Degradation Timeline

  • Weeks 1 to 12 (Phase 1): Upon injection, the CMC gel provides immediate volume correction. However, endogenous macrophages gradually dissolve and absorb the CMC carrier over the first 8 to 12 weeks. Patients frequently notice a slight softening of initial volume around week 6 to 8 as the aqueous gel dissipates before dense neo-collagen has fully formed.
  • Months 3 to 12+ (Phase 2): As the gel carrier metabolizes, the microspheres form a porous scaffold. Tissue histopathology confirms that host fibroblasts infiltrate the micro-scaffold, depositing Type I collagen, Type III collagen, elastin, and proteoglycans, alongside localized neo-vascularization (angiogenesis).
  • Months 12 to 18+ (Metabolic Dissolution): The CaHA microspheres slowly dissolve through normal physiological pathways, breaking down into calcium and phosphate ions, which are cleared via renal excretion or integrated into normal bone turnover. What remains long after the microspheres disappear is the patient's own newly generated endogenous collagen matrix.

Area-by-Area SSED Clinical Trial Deep Dive

Under FDA Class III Premarket Approval (product code LMH for aesthetic dermal implants; dorsal hands under PKY), Merz submitted separate clinical trials for each indication:

+---------------------------------------------------------------------------------------------------------+
|                               Summary of FDA SSED Trials Across Radiesse Indications                     |
+----------------------+-------------+--------------------+-----------------------+-----------------------+
| Indication           | PMA Number  | Key Primary Visit  | Final Tabulated Visit | Labeled IFU Statement |
+----------------------+-------------+--------------------+-----------------------+-----------------------+
| Nasolabial Folds     | P050052     | Month 3 primary:  | Month 6 secondary:  | Unknown beyond 3 yr;  |
| (Aesthetic Facial)   | ORIG (2006) | 84.6% vs collagen | 78.6% vs collagen   | Up to 2 yr in FAQ     |
|                      |             | (N=117 folds)     | (N=117)             |                       |
+----------------------+-------------+--------------------+-----------------------+-----------------------+
| Dorsal Hands         | P050052     | Month 3: 75.3% vs  | Month 12: 68.2%       | Unknown beyond 1 yr;  |
| (Augmentation)       | /S049 (2015)| 3.4% control (N=85)| (15/22 unretreated)   | Nodules last up to 1y |
+----------------------+-------------+--------------------+-----------------------+-----------------------+
| Jawline Contour      | P050052     | Week 12: 75.6% vs  | Week 48: 67.3%        | RADIESSE (+) only;    |
| (Loss of Contour)    | /S129 (2021)| 8.8% delayed (N=123| (76/113; not nested   | Adults over 21        |
|                      |             | )                  | in the original 93)   |                       |
+----------------------+-------------+--------------------+-----------------------+-----------------------+
| Décolleté Wrinkles   | P050052     | Week 24: 71.2% vs  | Week 60: 60.7%        | Diluted 1:2 saline;   |
| (Chest Rhytids)      | /S162 (2026)| 6.3% control (N=116| (54/89 observed cases)| 3 sessions (D1,W6,W12)|
+----------------------+-------------+--------------------+-----------------------+-----------------------+
| HIV Facial           | P050037     | Month 3: 100% GAIS | Month 6: 100% GAIS    | Reconstructive lipo-  |
| Lipoatrophy          | ORIG (2006) | improved (N=100)   | improved (N=98)       | atrophy; cheek thick. |
+----------------------+-------------+--------------------+-----------------------+-----------------------+

1. Nasolabial Folds (PMA P050052 Original, December 22, 2006)

  • Trial Design: Prospective, randomized, multicenter, split-face clinical trial evaluating 117 subjects. Each patient received Radiesse in one nasolabial fold and a commercially available human collagen dermal implant in the contralateral fold. Published trial reports identify that control as CosmoPlast.
  • Blinded Evaluator Endpoints: Assessed on the 6-point Lemperle Rating Scale (LRS).
    • Month 3 primary (non-inferiority): 84.6% of Radiesse-treated folds scored at least 1 LRS point higher than collagen, 12.8% scored equally, and 2.6% scored lower.
    • Month 6 secondary (superiority): 78.6% of Radiesse-treated folds scored at least 1 LRS point higher than control. This is not the primary endpoint and is not a 12-to-18-month duration table.
  • The Bass 2010 Extension (The "Up to 2 Years" Source): The pivotal effectiveness tables stop at 6 months. Bass et al. then followed 102 of 117 subjects; van Loghem et al. note that the extension offered retreatment between 6 and 12 months to balance asymmetry, with follow-up to 39 months. At least 30 months after the last Radiesse treatment, 40% of folds remained clinically improved. That 40% is after the last injection, not proof that a typical unretreated fold lasts 2 years. For fold alternatives, review nasolabial fold treatment options.

2. Dorsal Hand Augmentation (PMA P050052/S049, June 4, 2015; Product Code PKY)

  • Indication: Subdermal implantation for hand augmentation to correct volume loss in the dorsal hands.
  • Trial Design: Multicenter randomized clinical trial enrolling 114 subjects (85 immediate treatment, 29 delayed-treatment controls).
  • Blinded Evaluator Endpoints: Evaluated on the Merz Hand Grading Scale (MHGS). Responders required a ≥1-point improvement on both hands concurrently.
    • Month 3 Primary Endpoint: 75.3% (64/85) of Radiesse subjects were responders, compared to 3.4% (1/29) of delayed-treatment controls. A site-level sensitivity analysis in the SSED found that excluding Site 7, both-hands MHGS responders were 65.5% at 3 months versus 75.3% with that site included.
    • Month 12 (Table 20): Among 113 treated subjects (immediate plus delayed-treatment crossover): 87/113 (77.0%) at 3 months, 82/113 (72.6%) at 6 months, 25/35 (71.4%) at 9 months, and 15/22 (68.2%) at 12 months.
  • Understanding the Denominator: The 68.2% figure at 12 months is the N=22 unretreated remainder, not 15/85. Mean retreatment volume was 3.25 cc. Mean initial volume in the pivotal cohort was 5.18 cc (both hands).
  • Safety Observation: Physician- and subject-reported nodule/lump/bump events were 11.5%, with recorded duration from 17 to 312 days. The IFU states that nodules, bumps, or lumps in the back of the hand can last up to 1 year. Compare this to Restylane Lyft for hands.

3. Jawline Contour (PMA P050052/S129, September 1, 2021)

  • Indication: Deep injection (subcutaneous and/or supraperiosteal) for the improvement of moderate to severe loss of jawline contour in adults over the age of 21. Approved exclusively for RADIESSE (+) with 0.3% lidocaine.
  • Trial Design: Multicenter randomized trial (123 immediate treatment, 57 delayed-treatment controls). Delayed-treatment patients could receive product after the Week-12 primary assessment.
  • Blinded Evaluator Endpoints: Assessed on the Merz Jawline Assessment Scale (MJAS).
    • Week 12 Primary Endpoint: 75.6% (93/123) of Radiesse (+) subjects achieved ≥1-point improvement, compared to 8.8% (5/57) in the control group.
    • Week 48 retained response: The SSED reports 76/113 (67.3%) patients still meeting responder criteria 48 weeks after their own initial treatment, among those who had responded at 12 weeks post-treatment and who had Week-48 MJAS data, before optional retreatment. 113 is larger than 93, so this is not 76 of Table 12's immediate-treatment responders; it is an observed-case retained-response analysis after treatment, including delayed-treatment patients after crossover.
  • Clinical Correction: Older clinic articles and our male aesthetic guide jawline filler for men historically listed Radiesse as off-label for jawline sculpting. Under PMA supplement S129 (decided September 1, 2021), RADIESSE (+) is on-label for jawline contouring. That identity correction is not a 12-month median.

4. Décolleté Wrinkles (PMA P050052/S162, March 31, 2026)

  • Indication: Subdermal implantation of RADIESSE diluted 1:2 with 0.9% sterile saline, using a 22-gauge flexible cannula, for the improvement of décolleté wrinkles in patients 22 and older. The trial mixed 1.5 mL RADIESSE with 3.0 mL saline per session.
  • Trial Design (NCT05163353): Panel-track randomized controlled trial in 152 women aged 30 to 65 (116 immediate treatment, 36 delayed controls). Decision date March 31, 2026; Merz announced April 8, 2026.
  • Treatment Protocol: Required three injection sessions spaced 6 weeks apart (Day 1, Week 6, and Week 12), with optional retreatment at Week 36 and study exit at Week 84. The treatment field was a defined central décolleté zone; the protocol prohibited injection over breast tissue.
  • Blinded Evaluator Endpoints: Assessed on the Merz Aesthetic Scale (MAS) Décolleté Wrinkles – At Rest.
    • Week 24 Primary Endpoint: Multiple-imputation responder rate was 71.2% in the treatment group versus 6.3% in delayed controls (Table 10; percentages without a printed n/N).
    • Observed Case Trajectory (Table 11): 69/95 (72.6%) at Week 24, 60/91 (65.9%) at Week 36, 63/86 (73.3%) at Week 48, and 54/89 (60.7%) at Week 60.
    • Week 84 Status: Table 11 prints no Week-84 MAS n/N. Investigator GAIS still showed any improvement in 80.2% of treatment-group patients at 84 weeks PII, and subject GAIS in 84.0%—those are not MAS responder rates. 81 of 116 treatment subjects were available at Week 84; availability is not a response rate.
  • Skin of Color Subgroup: Fitzpatrick Skin Types IV–VI demonstrated a 77.8% (21/27) observed MAS At Rest responder rate at Week 24. The study was not powered for FST subgroups.
  • Breast Imaging Safety: The GPSDP met on August 13, 2025, on décolletage filler indication and breast-imaging questions. A retrospective adjudication in the SSED reported no visible product on 69/69 post-treatment mammograms or breast ultrasounds. That retrospective set is not proof CaHA can never appear on MRI or CT, and Healio reports a separate FDA-required post-approval imaging study. The IFU still tells patients to inform the radiologist.
  • Promotional vs. Clinical Data: Merz's April 8, 2026 press line that 83% would repeat treatment matches the SSED's Week-60 likelihood-of-retreatment survey (73/88, 83.0%), not Table 10. "More than 80% felt satisfied with skin tightness" is a press rounding of a different questionnaire (SSED: 76/116, 85.4%, appearance of tightened skin at Week 24). "90% of healthcare providers reported visible improvements by 4 months" is a press/data-on-file line, not Table 10 or Table 11.

5. HIV Facial Lipoatrophy (PMA P050037 Original, December 22, 2006)

  • Indication: Restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus.
  • Trial Results: Evaluated in 100 patients. Live GAIS showed 100% improvement at Month 3 (N=100) and Month 6 (N=98)—26% "very much improved," 72% "much improved," and 2% "improved" at 3 months. Mean left-cheek thickness went from 4.7 mm at baseline to 7.3 mm at 3 months and 7.1 mm at 6 months (right cheek 4.9 mm to 7.5 mm at 6 months).
  • Clinical Boundary: Do not cite P050037 100% GAIS to promise cosmetic nasolabial-fold success. Mean initial volume was 4.8 mL, plus 1.8 mL at 1 month in 85% of patients and 2.4 mL at 6 months in 89%. Those volumes and that deficit are not the aesthetic NLF trial.

The Hyperdilute Reality: Labeled 1:2 Décolleté vs. Off-Label Body Tightening

In recent years, "Hyperdilute Radiesse" has become one of the most aggressively marketed procedures for skin laxity on the neck, décolletage, upper arms, abdomen, buttocks, and above the knees.

However, clinicians and consumers must maintain clear regulatory boundaries:

                  [Hyperdilute Regulatory & Dilution Spectrum]

  Dilution Ratio    Target Area              FDA Regulatory Status   Delivery Method
  ──────────────    ───────────────────────  ─────────────────────   ───────────────────────────────
  1:0 (Undiluted)   Nasolabial folds, hands  On-label P050052 ORIG    Deep subdermal
                    RADIESSE (+) jawline     / S049 / S129            / supraperiosteal
  1:2               Décolleté wrinkles       On-label S162 (2026)     22G cannula; 3 sessions
                    (Merz FAQ: "hyperdiluted")                        1.5 mL + 3.0 mL saline
  1:3 to 1:6+       Neck, arms, abdomen,     Off-label; no US PMA     Cannula fanning protocols
                    buttocks, knees          duration table
  1. Supplement S162 is Specific to the Décolleté: The March 31, 2026 approval of P050052/S162 establishes that a 1:2 saline dilution delivered via a 22-gauge cannula across three sessions is safe and effective for décolleté wrinkles. It does not grant FDA approval for neck tightening, upper arm skin crepiness, abdominal laxity, or buttock biostimulation. Merz's consumer FAQ now uses "hyperdiluted RADIESSE" for that labeled 1:2 chest mix. That branding is not a license for 1:3–1:6 body protocols.
  2. Zero PMA Trade Names for "Hyperdilute": FDA PMA trade-name listings for this family do not include a product called "hyperdilute." Labeled décolleté is still RADIESSE Injectable Implant under S162. Body applications beyond hands and décolleté remain off-label.
  3. Existing Site Content Correction: Our guide on hyperdilute Radiesse dilution protocols currently identifies facial folds under P050037 and refers to the décolleté as off-label. P050052 is the aesthetic PMA, and décolleté 1:2 is on-label as of March 31, 2026.
  4. Duration Expectations Off-Label: There is no US PMA last-visit table for neck, arm, abdomen, buttock, or knee hyperdilute. Do not copy a 12-to-18-month facial envelope, a 4-year clinic body claim, or a 9-to-12-month consensus range onto those areas as if they were S162.

Non-Reversibility and Safety: What Cannot Be Undone

The most critical clinical distinction between calcium hydroxylapatite and hyaluronic acid fillers is reversibility:

                  [Reversibility & Complication Management]

    Hyaluronic Acid (Restylane, Juvéderm)            Calcium Hydroxylapatite (Radiesse)
  ┌────────────────────────────────────────┐  ┌────────────────────────────────────────────────┐
  │ • Fully reversible on demand           │  │ • NOT reversible with hyaluronidase            │
  │ • Hyaluronidase dissolves crosslinked  │  │ • CaHA microspheres cannot be enzymatically    │
  │   HA chains in minutes to hours        │  │   degraded by any available clinical agent     │
  │ • Vascular occlusion treated with      │  │ • Vascular occlusion cannot be reversed        │
  │   hyaluronidase on HA gels             │  │   with hyaluronidase; see dedicated VO page    │
  └────────────────────────────────────────┘  └────────────────────────────────────────────────┘
  • No Enzymatic Reversal: Injectable hyaluronidase cleaves the beta-(1,4) glycosidic bonds of hyaluronic acid. It has zero enzymatic effect on calcium hydroxylapatite or carboxymethylcellulose. If Radiesse is improperly placed, creates visible nodules, or is inadvertently injected intravascularly, it cannot be melted away. See our overview of dissolving filler with hyaluronidase.
  • Vascular Occlusion Risk: Accidental intra-arterial embolization of CaHA microspheres causes profound, immediate mechanical obstruction of capillary beds, leading to rapid skin necrosis, tissue loss, or irreversible blindness if injected into retrograde facial arterial branches. Because hyaluronidase cannot dissolve CaHA, management is significantly more difficult. We do not publish emergency treatment protocols on this site; injectors must be credentialed in advanced complication readiness. Review our analysis on filler vascular occlusion.
  • Nodule Formation:
    • Early technical nodules (Weeks 1 to 4): Superficial placement or large un-massaged boluses can create palpable or visible white mounds under thin skin, especially on the hands (IFU: nodules can last up to 1 year).
    • Late inflammatory nodules: Uncommon delayed reactions are described in the filler literature. In-office management is injector-dependent; some nodules require excision. This page does not publish a medication protocol.
  • Radiopacity on Diagnostic Imaging: Calcium hydroxylapatite is radiopaque. The IFU states the microspheres can be seen on X-rays and CT scans, and that patients should tell imaging clinicians they have had RADIESSE or RADIESSE (+). A clinical study in the décolleté SSED found no visible product on 69/69 post-treatment mammograms or breast ultrasounds; patients should still inform the radiologist.

Who Should Skip a Radiesse Quote?

A responsible aesthetic consultation clarifies who is not a candidate for calcium hydroxylapatite:

  1. Anyone Quoting Lips or Periocular Tear Troughs: The IFU states it is not known if RADIESSE or RADIESSE (+) is safe or effective in the lips or in the area around the eyes. Injecting CaHA into the vermilion or tear trough can produce persistent white or yellowish nodules—not an HA Tyndall effect. For under-eyes, consider Restylane Eyelight duration or surgical blepharoplasty.
  2. First-Time Filler Patients Wanting a "Trial Run": If a patient has never received dermal filler and is anxious about whether they will like their post-treatment aesthetic contour, they should never start with Radiesse. First-time patients should select a soft, reversible hyaluronic acid filler.
  3. Patients Seeking Multi-Year Body Tightening on a Single Syringe: Off-label neck, arm, abdomen, and buttock hyperdilute has no US PMA duration table. A single 1.5 mL syringe is not a body-tightening license, and S162's three-session 1:2 chest protocol does not transfer.
  4. Pregnancy and Breastfeeding: Safety has not been established in pregnant or nursing women; treatment should be deferred.
  5. Quotes That Conceal the Syringe Formulation: A clinic quote that states "Radiesse treatment: $750" without specifying whether the syringe contains Radiesse (1.5 cc without lidocaine), RADIESSE (+) (1.5 cc with factory 0.3% lidocaine), or an off-label dilution cannot be verified against FDA clinical duration tables.

Cost: What a Quote Has to Name

Radiesse is commonly sold as a 1.5 mL syringe (historical PMA trade names also include other volumes). The S162 décolleté trial used three sessions of 1.5 mL product diluted 1:2. Cash-pay prices vary by market and injector; a number without the SKU, area, dilution, and session count cannot be mapped to these tables. For a general syringe-pricing map, see lip filler cost per syringe. For material shopping rather than duration, see Sculptra vs. Radiesse.

Five Questions to Ask Your Injector Before Treatment

  1. "Are you using RADIESSE or RADIESSE (+), and what is the exact volume per syringe?"
    Why to ask: Confirms the presence of factory-integrated lidocaine (crucial for comfort in deep supraperiosteal jawline injections) and ensures you receive a full 1.5 cc syringe.
  2. "If treating my chest, are you following the FDA-approved S162 protocol (1:2 saline dilution with a 22G cannula over three sessions)?"
    Why to ask: Validates that the provider is following the proven clinical trial regimen rather than an unstandardized single-session approach.
  3. "If treating my jawline, is this RADIESSE (+), and are you injecting deep (subcutaneous and/or supraperiosteal) as labeled?"
    Why to ask: S129 is RADIESSE (+) only, in adults over 21, for deep injection. A quote of plain Radiesse, or a superficial plane, is not the labeled jawline table.
  4. "What is your protocol for non-reversible vascular occlusion, and do you keep an emergency kit on site?"
    Why to ask: Ensures the provider recognizes that hyaluronidase will not dissolve CaHA and possesses advanced emergency readiness.
  5. "Do you ever inject Radiesse into the lips or under the eyes?"
    Why to ask: An injector who recommends Radiesse for lips or tear troughs violates fundamental safety guidelines and should be avoided.

Frequently Asked Questions

How long does Radiesse last compared to Juvéderm or Sculptra?

There is no single Radiesse duration to line up against a single Juvéderm or Sculptra number. Nasolabial-fold Radiesse has a 6-month SSED superiority table versus collagen and a Bass extension in which 40% of folds remained improved at ≥30 months after the last treatment. Juvéderm Voluma XC cheeks showed 67.1% responders at Month 24 in P110033—a different product, area, and scale. Sculptra (PLLA) is a delayed-onset biostimulator with a longer marketed envelope; that comparison belongs on Sculptra vs. Radiesse, not as a Radiesse median.

How long does Radiesse last in the hands versus the jawline versus the chest?

  • Dorsal Hands: IFU unknown-beyond 1 year. Pivotal MHGS 64/85 (75.3%) at 3 months; Table 20 15/22 (68.2%) at 12 months among the unretreated remainder of 113 treated subjects.
  • Jawline (RADIESSE (+) only): 93/123 (75.6%) MJAS responders at Week 12; 76/113 (67.3%) retained response at Week 48 in the SSED's observed-case analysis after treatment—not 76 of the original 93.
  • Décolleté: After three 1:2 sessions, MAS At Rest was 71.2% (multiple imputation) at Week 24 and 54/89 (60.7%) observed at Week 60. No Week-84 MAS table.

Does Radiesse really last 2 years?

Not as a typical or median result. The consumer FAQ's "up to 2 years" cites Bass 2010. In that extension, 40% of nasolabial folds remained improved at ≥30 months after the last treatment, after retreatment was offered between 6 and 12 months. Sixty percent of evaluated folds were no longer scored improved. That is not the P050052B 6-month table, and it is not décolleté Week 60.

Is hyperdilute Radiesse FDA-approved, and how long does it last?

1:2 saline dilution in the décolleté is labeled under P050052/S162 (March 31, 2026). Merz's consumer FAQ now calls that mix "hyperdiluted." 1:3+ protocols for neck, arms, abdomen, and buttocks remain off-label in the United States, with no PMA duration table. Do not apply S162 Week-60 rates or a 12-to-18-month facial envelope to those areas.

Can Radiesse be dissolved if I do not like the result?

No. Hyaluronidase does not degrade calcium hydroxylapatite or the CMC carrier. Overfill and nodules have to be managed in-office over time, and some nodules are excised. See dissolving filler with hyaluronidase for the HA contrast; this page does not publish a CaHA reversal protocol.

Does Radiesse show up on a mammogram or CT scan?

The IFU states the microspheres can be seen on X-rays and CT scans. In S162, a retrospective review found no visible product on 69/69 post-treatment mammograms or breast ultrasounds. Patients receiving décolleté injections should still tell the radiologist. Healio reports a separate post-approval imaging study required by FDA.

Sources

Topics
RadiesseBiostimulatorsDermal FillersCostSafetyRegulatory
Ran Chen
Contributing Editor
Ran Chen

Founder, AestheticMedGuide. Life-sciences operator covering aesthetic devices, injectables, and the industry behind them. Previously global market-access lead across pharma and medtech.

Follow on LinkedIn →

Keep reading from Injectables

See all →
Injectables · 14 min read

Is HArmonyCa FDA Approved? Hybrid HA + CaHA Filler Status in the US

HArmonyCa is a hybrid HA plus CaHA filler with CE Mark and a 2026 Canadian launch. It is not FDA-approved. How to read MAUDE noise, the China Phase 3…

Injectables · 22 min read

How Long Does Restylane Last? Product-by-Product PMA Duration, Not One Family Number

How long Restylane lasts is product- and area-specific PMA data. Manufacturer up-to numbers are ceilings with touch-up, not medians. Contour is not…

Injectables · 15 min read

How Long Does Juvéderm Last? Product-by-Product PMA Duration, Not One Family Number

How long Juvéderm lasts is product- and area-specific PMA data. Manufacturer up-to numbers are ceilings with touch-up, not medians. Volbella is not…